This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M31.0 | Special Copayment Reduction: V135 (rare disease Special Copayment Reduction) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood: high — age at onset has a bimodal distribution, occurring mainly in young adult men in their 20s–30s and older women in their 60s–70s. Pediatric onset is extremely rare, and most patients are first diagnosed as adults. |
| 1. History | 1919: first described by Goodpasture → 1958: Stanton and Tange, 'pulmonary hemorrhage–nephritis syndrome' → 1967: Lerner et al. discovered anti-GBM antibodies → 1973: limited plasma exchange introduced. |
| 2. Causes | Anti-GBM antibodies (mainly IgG1/IgG4) bind to the NC1 domain of α3(IV) collagen → damage to glomerular and alveolar basement membranes. HLA-DRB1*1501 susceptibility; smoking and hydrocarbon exposure are triggers. |
| 3. Genetics | Strong susceptibility with HLA-DRB1*1501 (80% of patients); HLA-DR7/DR1 protective. α3(IV) collagen gene variants rarely overlap with Alport syndrome. |
| 4. General epidemiology | About 0.5–1.8 per 100,000 per year; bimodal distribution (men in their 20s–30s, women in their 60s–70s); about 1–2% of all glomerulonephritis. |
| 5. Pathophysiology | Anti-GBM antibodies (IgG) → binding to α3(IV)NC1 epitopes → complement activation + neutrophil recruitment → destruction of the glomerular basement membrane → crescent formation (crescentic GN) + alveolar hemorrhage. |
| 6. Symptoms | Pulmonary hemorrhage (hemoptysis, dyspnea) + rapidly progressive glomerulonephritis (hematuria, proteinuria, acute kidney failure). In nonsmokers, the kidney-limited form without lung involvement is more common. |
| 7. Signs | Urine: hematuria, red blood cell casts, proteinuria; chest X-ray: diffuse pulmonary opacities; anti-GBM antibody positive (serum); kidney biopsy: linear IgG deposition + crescentic glomerulonephritis. |
| 8. Screening | With a combination of unexplained hemoptysis + glomerulonephritis, immediate anti-GBM antibody + ANCA testing. Suspect with sudden hemoptysis in smokers. |
| 9. Diagnosis | Anti-GBM antibody ELISA (serum) + kidney biopsy (linear IgG deposition + crescentic GN). With lung involvement, alveolar hemorrhage confirmed by BAL. |
| 10. Treatment | Immediate plasma exchange (removal of anti-GBM antibodies) + steroids (pulse) + cyclophosphamide. With dialysis dependence + 100% crescents, reconsider plasma exchange. |
| 11. Prognosis | If Cr is <600 μmol/L at the start of treatment, renal function can recover. With 100% crescents + dialysis dependence, renal function does not recover. Relapse is rare but more frequent in double-positive patients. |
| 12. Prevention | Smoking cessation (prevention of lung involvement); avoidance of hydrocarbon exposure; kidney transplantation after confirming anti-GBM antibody negativity following treatment; prevention of complications of immunosuppression. |
| 13. References | 10 major international journals and guidelines |
The history of Goodpasture syndrome originates from a case report published in 1919 by the American physician Ernest William Goodpasture. Reporting the case of an 18-year-old man who died of simultaneous pulmonary hemorrhage and glomerulonephritis during the 1918 influenza pandemic, he first described the existence of this unusual syndrome involving both the lungs and kidneys. At the time, however, the association with influenza infection was emphasized, and it was not recognized as a separate autoimmune disease.
In the 1950s, systematic recognition of this syndrome developed. In 1958, Michael Stanton and James Tange compiled cases in which pulmonary hemorrhage and rapidly progressive glomerulonephritis occurred together and formally used the name 'Goodpasture's syndrome'. Although the immune mechanism was unclear at this time, its independent existence as a clinical syndrome was established.
The decisive breakthrough came in 1967, when Robert Lerner and colleagues discovered antibodies in the serum of patients with this syndrome that bind linearly to the renal glomerular basement membrane (GBM). This anti-GBM antibody was later confirmed as the key pathogenic agent of Goodpasture disease, and in the 1970s–80s its target was identified as the non-collagenous domain 1 of the α3 chain of type IV collagen of the GBM (α3(IV)NC1). With the introduction of plasmapheresis in 1973, treatment outcomes improved greatly, and immunoadsorption plasma exchange was shown to be effective in removing anti-GBM antibodies. In Korea, it is managed under the M31.0 (Goodpasture syndrome) code and Special Copayment Reduction V135.
The cause of Goodpasture syndrome is the formation of anti-glomerular basement membrane (anti-GBM) antibodies; it is an autoimmune disease in which these antibodies attack the basement membranes of the kidneys and lungs simultaneously.
Target antigen of anti-GBM antibodies: The autoantigen of Goodpasture disease is the non-collagenous domain 1 of the α3 chain of type IV collagen (α3(IV)NC1), present in both the glomerular basement membrane and the alveolar basement membrane. This domain has two major epitopes (E(A) and E(B)), and in most patients IgG antibodies (mainly IgG1 and IgG4 subclasses) against these epitopes are detected. Because the α3 chain of type IV collagen is specifically expressed in the glomerular basement membrane and proximal tubular basement membrane of the kidney and in the alveolar capillary basement membrane of the lung, these sites are selectively involved.
Triggers of the autoimmune response: Normally, the α3(IV)NC1 epitopes are not exposed to the immune system, but an autoimmune response is triggered when the following conditions alter the basement membrane structure and expose the epitopes. First, cigarette smoking increases alveolar basement membrane permeability and the risk of pulmonary hemorrhage, explaining why lung involvement is rare in nonsmokers. Second, hydrocarbon inhalation and organic solvent exposure can expose GBM epitopes by inducing kidney injury. Third, viral infections (influenza, HIV, etc.) also act as triggers. Fourth, 'double positive' patients who are simultaneously positive for ANCA (mainly MPO-ANCA) account for about 25–30%, and a mechanism has been proposed in which ANCA first damages the renal endothelium, exposing the α3(IV)NC1 epitopes.
Genetic susceptibility: HLA-DRB1*1501 is the strongest susceptibility allele, found in about 80% of patients with Goodpasture disease. In contrast, HLA-DR7 and HLA-DR1 are reported to have protective effects.
Goodpasture syndrome is not a single-gene disease but an autoimmune disease arising from the interaction of genetic susceptibility and environmental factors. In genetic studies, the association with HLA molecules is the best established.
HLA association: HLA-DRB1*1501 (a subtype of HLA-DR15) is the HLA allele most strongly associated with Goodpasture disease; it is present in about 80% of patients, much higher than its frequency in the general population (about 25%). HLA-DRB1*1501 is explained as efficiently presenting the E(A) epitope of α3(IV)NC1 to CD4+ T cells, promoting the autoimmune response. HLA-DR7 (DRB1*0701) and HLA-DR1 (DRB1*0101) are reported to have negative associations and a protective role against the disease. This protective effect is explained by these alleles interfering with binding to α3(IV)NC1 epitopes, thereby suppressing activation of autoreactive T cells.
Relationship between α3(IV) collagen and Alport syndrome: In patients with Alport syndrome, caused by mutations in the α3, α4 and α5 chains of type IV collagen (COL4A3, COL4A4, COL4A5 genes), anti-GBM antibodies against α3(IV)NC1 of the normal donor kidney sometimes form after kidney transplantation. This is understood as follows: because immune tolerance to the α3(IV) chain is not established from birth in patients with Alport syndrome, they mount an immune response to normal α3(IV) first encountered through the transplanted kidney. This is called 'post-transplant anti-GBM disease in Alport nephritis' and is managed separately from Goodpasture syndrome.
Other genetic factors: There are research reports that PTPN22 gene polymorphisms and immunoglobulin Fc receptor gene variants are also associated with susceptibility to anti-GBM disease, but the role of genetic factors other than HLA-DRB1*1501 is still understood to be secondary.
Goodpasture syndrome (anti-GBM disease) is a very rare autoimmune disease, with an annual incidence reported at about 0.5–1.8 per million population. It accounts for about 1–2% of all patients with glomerulonephritis and 10–15% of the causes of rapidly progressive glomerulonephritis (RPGN).
Age and sex distribution: Goodpasture syndrome is characterized by a bimodal distribution by age and sex. The first peak occurs in young men in their 20s–30s, and the second in older women in their 60s–70s. In young men, typical Goodpasture syndrome with both pulmonary hemorrhage and glomerulonephritis is common, whereas in older women, kidney involvement only without lung involvement (renal-limited variant) is more common.
Association with smoking: The proportion of smokers is markedly higher among patients with pulmonary hemorrhage, and smoking increases the permeability of the alveolar basement membrane, facilitating access of anti-GBM antibodies to the alveoli. In nonsmokers, lung involvement is rare, and the disease often presents as the renal-limited form.
Epidemiology of double-positive patients: 'Double-positive' patients who are simultaneously positive for anti-GBM antibodies and ANCA (mainly MPO-ANCA) account for about 25–30%. These patients tend to show a clinical course more similar to patients with ANCA-associated vasculitis alone than to patients with anti-GBM alone, and their risk of relapse is higher than with anti-GBM alone.
Epidemiology in Korea: The number of patients with Goodpasture syndrome (anti-GBM disease) in Korea is extremely small, estimated at fewer than several dozen. One study reported that about 8–15% of Korean patients with rapidly progressive glomerulonephritis were anti-GBM antibody-related. It is registered and managed under Special Copayment Reduction V135.
The pathogenesis of Goodpasture syndrome centers on autoantibody-mediated tissue injury, and because the basement membranes of the kidney and lung share the same autoantigen (α3(IV)NC1), both organs are involved simultaneously.
Process of anti-GBM antibody formation: When α3(IV)NC1 epitopes are recognized by CD4+ T cells (Th1-skewed) in HLA-DRB1*1501-positive individuals, B cells receiving T cell help are activated and produce IgG autoantibodies specific for α3(IV)NC1. These antibodies consist mainly of the IgG1 and IgG4 subclasses.
Mechanism of glomerular basement membrane injury: When circulating anti-GBM antibodies bind directly to α3(IV)NC1 of the renal glomerular basement membrane (linear IgG deposition pattern), the complement system (classic pathway) is activated. Glomerular endothelial cells are damaged by complement breakdown products (C3a, C5a, MAC), and neutrophils and monocytes are recruited. The recruited effector cells release proteases and reactive oxygen species, destroying the glomerular basement membrane. Proteins and red blood cells leak through the damaged glomerular basement membrane, and fibrin deposition and cell proliferation occur within Bowman's space, producing the characteristic crescent formation. When crescents form in 50% or more of glomeruli, it is called crescentic glomerulonephritis (crescentic GN), and Goodpasture syndrome is one of the main causes of this form.
Mechanism of pulmonary basement membrane injury: The same anti-GBM antibodies bind to α3(IV)NC1 of the alveolar capillary basement membrane and damage the alveolar wall. However, the antibodies can reach the basement membrane only when alveolar basement membrane permeability is increased by smoking, lung infection, pulmonary edema or the like, so lung involvement may be absent in nonsmokers or in the absence of lung injury. Alveolar hemorrhage manifests as leakage of red blood cells into the alveoli and hemosiderin accumulation in macrophages.
The clinical presentation of Goodpasture syndrome (anti-GBM disease) is broadly divided into three types: typical Goodpasture syndrome involving both the lungs and kidneys (about 60–70%), the renal-limited form involving only the kidneys (about 20–30%), and the lung-limited form involving only the lungs (about 5–10%).
Pulmonary symptoms: Alveolar hemorrhage (diffuse alveolar hemorrhage, DAH) is the most dangerous pulmonary manifestation, and hemoptysis is the characteristic symptom. Hemoptysis ranges from blood-streaked sputum to life-threatening massive bleeding. Besides hemoptysis, dyspnea, cough, fever and chest pain may accompany it. Almost all patients with lung involvement have a history of smoking. Pulmonary symptoms often precede renal symptoms by days to weeks.
Renal symptoms: These present as the clinical picture of rapidly progressive glomerulonephritis (RPGN). Macroscopic hematuria appears as dark red-brown urine, and microscopic hematuria, red blood cell casts and proteinuria are characteristic. The glomerulonephritis progresses rapidly, and acute kidney failure (edema, oliguria, hypertension) develops within days to weeks. If untreated, it progresses to end-stage renal disease (ESRD) within weeks.
Systemic symptoms: In Goodpasture syndrome, systemic symptoms (fever, weight loss) tend to be less prominent than in other systemic vasculitides. However, fatigue and generalized weakness are common, becoming worse particularly when acute kidney failure and anemia are present.
Double-positive patients: In patients simultaneously positive for anti-GBM antibodies and MPO-ANCA, relapse is more frequent than with Goodpasture syndrome alone, and other findings of ANCA-associated vasculitis (nasal, sinus and lung involvement) may additionally appear.
The physical signs and test findings of Goodpasture syndrome are key to the diagnosis and directly determine treatment direction.
Urinalysis findings: hematuria (microscopic or macroscopic), red blood cell casts (RBC cast) — a marker of glomerulonephritis; proteinuria (moderate or greater). These findings strongly suggest rapidly progressive glomerulonephritis and should lead to immediate anti-GBM antibody and ANCA testing.
Pulmonary findings: Diffuse bilateral alveolar infiltrates across both lungs on chest X-ray or CT are characteristic findings of alveolar hemorrhage. Alveolar hemorrhage is confirmed when bronchoalveolar lavage (BAL) shows bloody lavage fluid and hemosiderin-laden macrophages.
Serum anti-GBM antibodies: A positive serum anti-GBM antibody is the key diagnostic criterion for Goodpasture disease. ELISA is the standard test, with very high sensitivity of 86–100% and specificity of 95–100%. MPO-ANCA should be measured at the same time to determine double positivity.
Kidney biopsy findings: The findings essential for confirming Goodpasture disease are as follows. ① Light microscopy: crescent formation in 50% or more of glomeruli (crescentic GN), intraglomerular fibrin deposition, cell proliferation. ② Immunofluorescence microscopy: IgG deposition distributed linearly along the glomerular basement membrane — the pathologically specific finding of Goodpasture disease. It is distinguished from granular or segmental deposition in other glomerulonephritides. ③ Electron microscopy: characterized by the absence of immune complex deposits (direct antibody binding).
Renal function markers: Serum creatinine rises rapidly and the glomerular filtration rate (GFR) falls sharply. Elevated BUN and electrolyte abnormalities (hyperkalemia, metabolic acidosis) are markers of renal failure.
There is no population-wide screening test for Goodpasture syndrome. However, because the disease progresses to irreversible renal failure within days to weeks, immediate screening evaluation is needed when it is clinically suspected.
Indications for immediate screening: Anti-GBM antibody testing should be performed immediately in the following situations. ① unexplained hemoptysis accompanied by hematuria or glomerulonephritis; ② patients with rapidly progressive glomerulonephritis (sharp rise in creatinine within days to weeks); ③ evaluation of the cause of alveolar hemorrhage; ④ red blood cell casts found on urinalysis.
Initial screening tests: urinalysis (urine sediment: red blood cell casts, microscopic hematuria, proteinuria); serum creatinine, BUN, electrolytes; complete blood count (checking for anemia); anti-GBM antibody ELISA (serum); MPO-ANCA, PR3-ANCA; chest X-ray and/or chest CT; complement (C3, C4) — typically normal in Goodpasture (differentiation from immune complex diseases).
Importance of rapid diagnosis: Once anti-GBM antibody positivity + glomerulonephritis is confirmed, the situation is so urgent that treatment should start immediately without waiting for kidney biopsy results. The serum creatinine level at the start of treatment is the most important predictor of whether renal function will recover.
The diagnosis of Goodpasture syndrome is confirmed by integrating clinical symptoms, serum anti-GBM antibody testing and kidney biopsy findings.
Serum anti-GBM antibody testing: ELISA (enzyme-linked immunosorbent assay) is the standard diagnostic method, with sensitivity of 86–100% and specificity of 95–100%. Rapid tests (rapid immunoassay) can also be used in emergencies. Antibody titers correlate with disease activity and are used to monitor the course of treatment. MPO-ANCA and PR3-ANCA are also measured at the same time to determine double positivity.
Kidney biopsy: Even in patients positive for serum anti-GBM antibodies, kidney biopsy is performed for histological confirmation and to determine the proportion of crescent formation for prognostic prediction. Crescentic glomerulonephritis on light microscopy and linear IgG deposition on immunofluorescence are the pathological confirmatory findings. When crescents form in >50% of glomeruli, the likelihood of renal recovery is markedly reduced.
Pulmonary evaluation: Confirmation of an alveolar hemorrhage pattern (ground-glass opacities, diffuse alveolar infiltrates) on chest CT. Bloody lavage fluid and hemosiderin-laden macrophages on bronchoalveolar lavage (BAL) — confirms alveolar hemorrhage. An increased DLco (diffusing capacity for carbon monoxide) on pulmonary function testing reflects the presence of hemoglobin within the lungs.
Differential diagnosis: Differentiation from ANCA-associated vasculitis (MPO-ANCA + lung involvement + glomerulonephritis), lupus nephritis, microscopic polyangiitis, IgA nephropathy, cryoglobulinemic vasculitis and others is necessary.
In Goodpasture syndrome (anti-GBM disease), renal function at the time treatment starts is the most important factor determining prognosis. Therefore, treatment must start immediately upon confirmation.
Plasma exchange (plasmapheresis/plasma exchange): Plasma exchange is the key treatment that rapidly removes circulating anti-GBM antibodies and inflammatory mediators (complement, cytokines). It is performed daily or every other day for a total of 7–14 sessions (2 weeks), exchanging 4 liters of plasma with 5% albumin (including some fresh frozen plasma in patients with pulmonary hemorrhage). The goal is to rapidly lower anti-GBM antibody titers and halt the progression of kidney damage.
Immunosuppressive treatment: Steroids (intravenous methylprednisolone pulse therapy 500–1,000 mg/day × 3 days followed by oral prednisolone 1 mg/kg/day) and cyclophosphamide (2–3 mg/kg/day orally or 15 mg/kg intravenously at 2–3 week intervals) are combined to suppress anti-GBM antibody production. Immunosuppressive treatment suppresses production of new antibodies while plasma exchange removes existing antibodies. After remission is achieved, cyclophosphamide is tapered over 3 months and steroids over 6–12 months.
Dialysis: When renal function at diagnosis has already declined to the level requiring dialysis and kidney biopsy shows crescents in >85–100% of glomeruli, the likelihood of renal recovery is very low, and plasma exchange may not contribute to renal recovery. However, current guidelines call for plasma exchange even in this case to control pulmonary hemorrhage. If anti-GBM antibodies remain negative for 6–12 months or more after starting dialysis, kidney transplantation may be considered.
New treatment options: Rituximab is increasingly used as adjunctive treatment in relapsing/refractory anti-GBM disease, targeting the B cells that produce anti-GBM antibodies. T cell costimulation blockers such as ipilimumab (CTLA4-Ig) are also at the research stage.
In Goodpasture syndrome (anti-GBM disease), renal function status at the start of treatment is the strongest predictor of prognosis. If treatment is started in a timely manner, renal function can be preserved in a considerable number of patients, but if diagnosis is delayed, irreversible loss of renal function occurs.
Predictors of renal recovery: If serum creatinine is <600 μmol/L (about 6.8 mg/dL) at the start of treatment, the likelihood of renal recovery is high. If the proportion of crescent formation on kidney biopsy is <50%, renal recovery is possible, but if it is >85–100%, renal recovery is difficult. When diagnosed in a dialysis-dependent state, the likelihood of renal recovery is reported to be less than about 10%.
Patient survival: With modern treatment (plasma exchange + immunosuppression), 1-year survival has improved to about 80–90%. The main causes of death are infection (a complication of immunosuppression), alveolar hemorrhage (massive hemoptysis) and renal failure.
Relapse: Relapse of anti-GBM disease is very rare, reported at <5%. This is understood to be because anti-GBM disease arises from a monoclonal B cell response, so relapse is uncommon once antibody titers disappear after treatment. In double-positive (anti-GBM + ANCA) patients, relapse of ANCA-associated vasculitis is possible.
Prognosis after kidney transplantation: When kidney transplantation is performed after anti-GBM antibodies have remained negative for 6–12 months or more, the risk of post-transplant recurrence of anti-GBM disease is low and transplant success rates are good. However, the risk of post-transplant anti-GBM disease in patients with Alport syndrome must be managed separately.
There is no direct primary prevention for Goodpasture syndrome. Management of environmental factors to minimize triggering of the autoimmune response and prevention of complications after treatment are central.
No smoking: Because smoking increases the permeability of the alveolar basement membrane and facilitates alveolar access of anti-GBM antibodies, smoking cessation is decisively important for preventing lung involvement in anti-GBM antibody-positive patients and high-risk groups (HLA-DRB1*1501-positive). Because smoking has often acted as a direct trigger of pulmonary hemorrhage in patients with pulmonary hemorrhage, smoking cessation must be counseled during treatment.
Avoidance of hydrocarbon and organic solvent exposure: In cases of occupational exposure to hydrocarbons and organic solvents, appropriate protective equipment is worn and exposure is minimized.
Management during and after treatment: Anti-GBM antibody titers are monitored regularly to assess treatment response, and immunosuppressive treatment is discontinued in stages after the antibodies become negative. During treatment, adequate fluid intake and mesna administration are used to prevent cyclophosphamide-induced bladder toxicity (hemorrhagic cystitis), and prophylactic antibiotics are given to prevent PCP (Pneumocystis carinii pneumonia).
Preparation before kidney transplantation: When kidney transplantation is considered in patients who have progressed to dialysis-dependent end-stage renal failure, transplantation is performed after serum anti-GBM antibodies have remained negative for at least 6–12 months, minimizing the risk of recurrence of anti-GBM disease in the transplanted kidney.
Patient education: Patients treated for anti-GBM disease are educated to notify their medical team immediately in the event of sudden recurrence of hematuria, recurrence of hemoptysis or a sharp decline in renal function. In double-positive patients (anti-GBM + ANCA), signs of relapse of ANCA-associated vasculitis (epistaxis, fever, arthralgia, etc.) are also monitored.
Goodpasture EW. The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci. 1919;158(6):863-870.
Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126(6):989-1004. PMID: 4170052.
Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture's disease (anti-GBM). J Autoimmun. 2014;48-49:108-112. DOI: 10.1016/j.jaut.2014.01.024.
Cui Z, Zhao MH, Hellmark T, Segelmark M. Natural recovery from antiglomerular basement membrane disease. Clin J Am Soc Nephrol. 2011;6(5):1100-1104. DOI: 10.2215/CJN.09931110.
McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. DOI: 10.2215/CJN.01380217.
Huart A, Josse AG, Chauveau D, Gómez Caminero A, Mahr A, Cohen P. Outcomes of patients with Goodpasture syndrome: a nationwide cohort-based study from the French Society of Nephrology. J Autoimmun. 2016;73:53-61.
Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-1042. PMID: 11388816.
Johnson JP, Moore J Jr, Austin HA 3rd, Balow JE, Antonovych TT, Wilson CB. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore). 1985;64(4):219-227. PMID: 4010929.
Canney M, O'Hara PV, McEvoy CM, et al. Spatial and temporal clustering of anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2016;11(8):1392-1399.
Dammacco F, Battaglia S, Gesualdo L, Racanelli V. Goodpasture's disease: a report of ten cases and a review of the literature. Autoimmun Rev. 2013;12(11):1101-1108.